Edgewise Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kevin Koch
- Full Time Employees
- 127
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1715 38th Street Boulder CO United States of America 80301
- IPO Date
- Mar 26, 2021
- CIK
- 0001710072
- Website
- edgewisetx.com
- Similar Companies
- Business
- Edgewise Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel precision medicines for the treatment of serious muscle diseases, including muscular dystrophies and cardiac conditions. Its core products include sevasemten (EDG-5506), an orally administered small molecule fast skeletal myosin inhibitor in late-stage clinical trials targeting Duchenne and Becker muscular dystrophies, and EDG-7500, a novel cardiac sarcomere modulator in Phase II clinical development for hypertrophic cardiomyopathy and other diseases of diastolic dysfunction. Additionally, the company develops a pipeline of precision medicine candidates targeting key muscle proteins to address genetically defined muscle disorders, leveraging a proprietary drug discovery platform based on integrated muscle function measurement in whole organ extracts. Founded in 2017 and headquartered in Boulder, Colorado, Edgewise Therapeutics operates primarily in the United States with clinical trials extending to the U.S., Israel, Europe, and Australasia. The company serves the biotechnology and healthcare sectors with a focus on muscle-focused therapeutics for patients with debilitating muscle diseases. Recent major developments include continued clinical progress in its muscular dystrophy and cardiac programs, with the GRAND CANYON Phase 2/3 trial enrolling 175 adults for Becker muscular dystrophy set to report topline results in Q4 2026, and Phase 3 engagement planned for Duchenne muscular dystrophy studies in 2026. The CIRRUS-HCM program update is expected in Q4 2025, and topline data for the EDG-15400 cardiac sarcomere modulator in Phase 1 is anticipated in the first half of 2026. Operational updates also include inducement equity grants related to new executive hires and a focus on building the world’s leading muscle-focused biopharmaceutical company. As of September 2025, the company reported cash and marketable securities of approximately $563.3 million to support its ongoing research and development efforts. Edgewise Therapeutics is dedicated to improving patient outcomes with a targeted muscle biology approach and operates with approximately 110 to 126 employees as per recent data. The company is publicly traded on NASDAQ under the ticker EWTX. This description reflects information current as of late 2025 and incorporates the company’s latest strategic clinical developments, financial position, and leadership changes.
Company News
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Biotech Options Buzz: UTHR, NMRA, EWTX
91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics Reports Improvements In Heart Drug Trial
Edgewise shares slip after heart-disease drug trial data disappoints investors
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal